

# **Influenza Work Group**

## **Introduction**

**Ruth Karron, MD**

**Advisory Committee on Immunization Practices**

February 26, 2014

# Influenza Work Group

## **ACIP Members**

Ruth Karron (Chair)

Jeff Duchin

Lee Harrison

## ***Ex Officio* Members**

Melisse Baylor (FDA)

David Cho (FDA)

Jesse Geibe (DoD)

Bruce Gellin (HHS)

Lucia Lee (FDA)

Cynthia Noletti (FDA)

Rachelle Salomon (NIH)

## **CDC Lead**

Lisa Grohskopf

(CDC/Influenza Division)

## **Liaison Representatives**

Kevin Ault (ACOG)

Hank Bernstein (AAP)

Jan Englund (PIDS)

Sandra Fryhofer (ACP; AMA)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Jamie Loehr (AAFP)

Kathy Neuzil (IDSA)

Lisa Ipp (SAHM)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Nadine Sicard (NACI)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Matthew Zahn (NACCHO)

## **Consultant**

Wendy Keitel

## **WG Discussion Since October 2013**

- Relative efficacy and safety of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) for children**
  - GRADE analyses
  - Safety surveillance update--Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
  
- LAIV Supply**
  
- Interim estimate of 2013-14 seasonal influenza vaccine effectiveness (US Flu VE Network)**

# LAIV Preferential Recommendations

## UK

“[LAIV]... is strongly recommended as the vaccine of choice for children aged two years up to 18 years in clinical risk groups...”

## Canada

“Based on effectiveness, efficacy and immunogenicity data, NACI recommends LAIV for use in healthy children and adolescents 2-17 years of age. Available data indicates that LAIV would be preferred over TIV in this population...”

## Israel

“The Live Attenuated [Influenza] Vaccine is preferable to the Inactivated [Influenza] Vaccine in children aged two to 17 due to its superior efficacy in this group.”

## Germany

“STIKO recommends that LAIV should be used preferentially for influenza vaccination of at-risk children aged 2-6 years.”

## Oregon

“The Oregon Immunization Program (OIP) preferentially recommends the use of Live Attenuated Influenza Vaccine (LAIV) in healthy children 2–5 years of age.”

## Washington State

“Data suggest that LAIV is more effective than inactivated influenza vaccine (IIV) for children 2 through 7 years of age. If a provider has access to both LAIV and IIV, they should consider using LAIV for healthy children 2 through 7 years.”

# Agenda Overview

- ❑ **Influenza Surveillance Update**
  - Lyn Finelli (CDC—Influenza Division)
- ❑ **Interim Vaccine Effectiveness Estimate, US Flu VE, Network, 2013-14**
  - Brendan Flannery (CDC—Influenza Division)
- ❑ **Relative Efficacy of LAIV vs. IIV for Children (GRADE)**
  - Lisa Grohskopf (CDC—Influenza Division)
- ❑ **Interim Influenza Vaccine Safety Update**
  - Maria Cano (CDC—Immunization Safety Office)
- ❑ **LAIV vs. IIV—Comparative Safety Studies in Children**
  - Emmanuel (Chip) Walter (Duke University)
- ❑ **Relative Safety of LAIV vs. IIV for children (GRADE)**
  - Lisa Grohskopf (CDC—Influenza Division)
- ❑ **LAIV Supply Update**
  - Kathleen Coelingh (MedImmune)
- ❑ **Annual Influenza Recommendations**
  - Lisa Grohskopf (CDC—Influenza Division)